COHERUS ONCOLOGY INC (CHRS) Stock Fundamental Analysis
USA - NASDAQ:CHRS - US19249H1032 - Common Stock
1.1 USD
-0.06 (-5.17%)
1.1 USD
0 (0%)
Taking everything into account, CHRS scores 2 out of 10 in our fundamental rating. CHRS was compared to 533 industry peers in the Biotechnology industry. CHRS may be in some trouble as it scores bad on both profitability and health. CHRS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CHRS has reported negative net income.
In the past year CHRS has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: CHRS reported negative net income in multiple years.
In the past 5 years CHRS reported 4 times negative operating cash flow.
1.2 Ratios
CHRS has a Return On Assets of 30.00%. This is amongst the best in the industry. CHRS outperforms 98.12% of its industry peers.
Looking at the Return On Equity, with a value of 176.56%, CHRS belongs to the top of the industry, outperforming 99.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30% | ||
| ROE | 176.56% | ||
| ROIC | N/A |
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 185.44%, CHRS belongs to the top of the industry, outperforming 99.06% of the companies in the same industry.
In the last couple of years the Profit Margin of CHRS has declined.
CHRS has a Gross Margin of 47.79%. This is in the better half of the industry: CHRS outperforms 75.05% of its industry peers.
In the last couple of years the Gross Margin of CHRS has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 185.44% | ||
| GM | 47.79% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
2. Health
2.1 Basic Checks
CHRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CHRS has more shares outstanding
Compared to 5 years ago, CHRS has more shares outstanding
The debt/assets ratio for CHRS has been reduced compared to a year ago.
2.2 Solvency
CHRS has an Altman-Z score of -4.19. This is a bad value and indicates that CHRS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CHRS (-4.19) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.58 indicates that CHRS is somewhat dependend on debt financing.
The Debt to Equity ratio of CHRS (0.58) is worse than 72.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.19 |
ROIC/WACCN/A
WACC7.85%
2.3 Liquidity
CHRS has a Current Ratio of 1.24. This is a normal value and indicates that CHRS is financially healthy and should not expect problems in meeting its short term obligations.
CHRS has a Current ratio of 1.24. This is amonst the worse of the industry: CHRS underperforms 85.37% of its industry peers.
CHRS has a Quick Ratio of 1.23. This is a normal value and indicates that CHRS is financially healthy and should not expect problems in meeting its short term obligations.
CHRS has a worse Quick ratio (1.23) than 84.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
The earnings per share for CHRS have decreased strongly by -19.27% in the last year.
CHRS shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -27.39% yearly.
CHRS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -72.54%.
The Revenue has been decreasing by -5.60% on average over the past years.
EPS 1Y (TTM)-19.27%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-3200%
Revenue 1Y (TTM)-72.54%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-83.65%
3.2 Future
Based on estimates for the next years, CHRS will show a decrease in Earnings Per Share. The EPS will decrease by -0.40% on average per year.
The Revenue is expected to decrease by -2.52% on average over the next years.
EPS Next Y-66.6%
EPS Next 2Y0.36%
EPS Next 3Y2.59%
EPS Next 5Y-0.4%
Revenue Next Year-82.03%
Revenue Next 2Y-38.64%
Revenue Next 3Y-27.94%
Revenue Next 5Y-2.52%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CHRS. In the last year negative earnings were reported.
Also next year CHRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.36%
EPS Next 3Y2.59%
5. Dividend
5.1 Amount
No dividends for CHRS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.1
-0.06 (-5.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners44.86%
Inst Owner Change-6.35%
Ins Owners6.31%
Ins Owner Change0%
Market Cap127.85M
Revenue(TTM)83.57M
Net Income(TTM)154.97M
Analysts81.82
Price Target5.78 (425.45%)
Short Float %28.46%
Short Ratio23.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.86%
Min EPS beat(2)-11.56%
Max EPS beat(2)-4.17%
EPS beat(4)0
Avg EPS beat(4)-46.06%
Min EPS beat(4)-108.91%
Max EPS beat(4)-4.17%
EPS beat(8)2
Avg EPS beat(8)-59.84%
EPS beat(12)5
Avg EPS beat(12)-37.55%
EPS beat(16)7
Avg EPS beat(16)-36.18%
Revenue beat(2)0
Avg Revenue beat(2)-8.12%
Min Revenue beat(2)-15.42%
Max Revenue beat(2)-0.81%
Revenue beat(4)1
Avg Revenue beat(4)-22.58%
Min Revenue beat(4)-86.37%
Max Revenue beat(4)12.3%
Revenue beat(8)3
Avg Revenue beat(8)-10.27%
Revenue beat(12)4
Avg Revenue beat(12)-11.09%
Revenue beat(16)4
Avg Revenue beat(16)-11.88%
PT rev (1m)0%
PT rev (3m)-12.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.09%
Revenue NQ rev (1m)-3.12%
Revenue NQ rev (3m)-6.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.53 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.46 | ||
| P/tB | 3.34 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.3
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.72
BVpS0.76
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30% | ||
| ROE | 176.56% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 185.44% | ||
| GM | 47.79% | ||
| FCFM | N/A |
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
F-Score4
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | -4.19 |
F-Score4
WACC7.85%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.27%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-3200%
EPS Next Y-66.6%
EPS Next 2Y0.36%
EPS Next 3Y2.59%
EPS Next 5Y-0.4%
Revenue 1Y (TTM)-72.54%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-83.65%
Revenue Next Year-82.03%
Revenue Next 2Y-38.64%
Revenue Next 3Y-27.94%
Revenue Next 5Y-2.52%
EBIT growth 1Y-33.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-86.53%
EBIT Next 3Y12.47%
EBIT Next 5Y7.38%
FCF growth 1Y65.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.55%
OCF growth 3YN/A
OCF growth 5YN/A
COHERUS ONCOLOGY INC / CHRS FAQ
What is the ChartMill fundamental rating of COHERUS ONCOLOGY INC (CHRS) stock?
ChartMill assigns a fundamental rating of 2 / 10 to CHRS.
Can you provide the valuation status for COHERUS ONCOLOGY INC?
ChartMill assigns a valuation rating of 0 / 10 to COHERUS ONCOLOGY INC (CHRS). This can be considered as Overvalued.
Can you provide the profitability details for COHERUS ONCOLOGY INC?
COHERUS ONCOLOGY INC (CHRS) has a profitability rating of 3 / 10.
How financially healthy is COHERUS ONCOLOGY INC?
The financial health rating of COHERUS ONCOLOGY INC (CHRS) is 2 / 10.